Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

Home

/

AUPH

A

Aurinia Pharmaceuticals Inc. (AUPH)

NGM – Цена в реальном времени. Валюта: USD

17.23

-0.32 (-1.82%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

17.27

+0.04 (0.23%)

После закрытия: Jun 26, 2026, 7:56 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million

Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million

814,606 common shares acquired for a total transaction value of approximately $12.5 million, based on a weighted average price of $15.29 per share. The purchase represents 6.66% of Kevin Tang's total holdings prior to the transaction, with direct ownership unchanged at zero shares post-transaction.

Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow

Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow

Aurinia Pharmaceuticals (AUPH) is positioned for profitable growth, driven by Lupkynis and pipeline expansion via the Kezar Life Sciences acquisition. AUPH delivered strong 1Q26 results: 24% revenue growth, 48% net income growth, and robust cash flow, reaffirming FY26 guidance for double-digit revenue gains. Tang Capital Management increased its stake above 10%, signaling confidence in AUPH's valuation and future pipeline or strategic optionality.

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death.

Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript

Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript

Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript

Parabolic AI rally has bulls eyeing a comeback for this one-time meme metal trade

Parabolic AI rally has bulls eyeing a comeback for this one-time meme metal trade

Silver prices surged 7% Monday to the highest since March.

Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates

Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago.

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress.

Видео

No Data

There is no data to display

Пресс-релизы

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death.

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress.

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right.

MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition

MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued the following statement in response to the Company's announcement that Kevin Tang has been appointed Chief Executive Officer, effective immediately. Antoine Khalife, Founder of MKT Capital, stated: “Today marks a watershed moment for Aurinia shareholders. Since 2019,.